Literature DB >> 20471706

Digoxin treatment in heart failure--unveiling risk by cluster analysis of DIG data.

Sameer Ather1, Leif E Peterson, Vijay G Divakaran, Anita Deswal, Kumudha Ramasubbu, Irakli Giorgberidze, Alvin Blaustein, Xander H T Wehrens, Douglas L Mann, Biykem Bozkurt.   

Abstract

BACKGROUND: Digoxin has been shown to reduce heart failure (HF) hospitalizations with no overall effect on mortality in HF patients. We used cluster analysis to delineate the clinical characteristics of HF patients in whom digoxin therapy was associated with improved or worsened clinical outcomes.
METHODS: The Digitalis Investigation Group (DIG) database was partitioned into 20 clusters. Multivariate Cox regression analyses was used, to identify clusters in which digoxin was associated with either an increase (Mortality(dig)HR>1), decrease (Mortality(dig)HR<1), or no association with all cause mortality (Mortality(dig)HR-NS); and separately, with an increase (HFA(dig)HR>1), decrease (HFA(dig)HR<1), or no association (HFA(dig)HR-NS) with HF admissions (HFA).
RESULTS: We identified 938 patients in the Mortality(dig)HR>1 group, 6818 patients in the Mortality(dig)HR-NS group, and none in Mortality(dig)HR<1 group. The Mortality(dig)HR>1 group had a higher prevalence of females, diabetes mellitus, hypertension, higher age, systolic blood pressure (SBP), heart rate and ejection fraction (EF), compared to the Mortality(dig)HR-NS group. Similarly, 6325 patients clustered in the HFA(dig)HR<1 group, 1431 patients in the HFA(dig)HR-NS group, and none in the HFA(dig)HR>1 group. The HFA(dig)HR-NS group had a higher prevalence of females and hypertension, higher SBP, body mass index and EF; and lower prevalence of peripheral edema and third heart sound, compared with the HFA(dig)HR<1 group.
CONCLUSION: Thus, the baseline characteristics of patients who did not have reduction in HF hospitalization or who had increased mortality were very similar and included females with hypertension, higher EF and higher SBP. Thus, use of digoxin in patients with this profile may need to be avoided. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20471706      PMCID: PMC2923690          DOI: 10.1016/j.ijcard.2010.04.021

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  13 in total

1.  Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study.

Authors:  M W Rich; F McSherry; W O Williford; S Yusuf
Journal:  J Am Coll Cardiol       Date:  2001-09       Impact factor: 24.094

Review 2.  The contemporary use of digoxin for the treatment of heart failure.

Authors:  Gary S Francis
Journal:  Circ Heart Fail       Date:  2008-09       Impact factor: 8.790

3.  The effect of digoxin on mortality and morbidity in patients with heart failure.

Authors: 
Journal:  N Engl J Med       Date:  1997-02-20       Impact factor: 91.245

4.  Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure.

Authors: 
Journal:  Control Clin Trials       Date:  1996-02

5.  Sex-based differences in the effect of digoxin for the treatment of heart failure.

Authors:  Saif S Rathore; Yongfei Wang; Harlan M Krumholz
Journal:  N Engl J Med       Date:  2002-10-31       Impact factor: 91.245

Review 6.  ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure).

Authors:  Sharon Ann Hunt
Journal:  J Am Coll Cardiol       Date:  2005-09-20       Impact factor: 24.094

7.  Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations.

Authors:  Ali Ahmed
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2007-03       Impact factor: 6.053

8.  Association of serum digoxin concentration and outcomes in patients with heart failure.

Authors:  Saif S Rathore; Jeptha P Curtis; Yongfei Wang; Michael R Bristow; Harlan M Krumholz
Journal:  JAMA       Date:  2003-02-19       Impact factor: 56.272

9.  Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy.

Authors:  Amandeep Singh Dhaliwal; Audrius Bredikis; Gabriel Habib; Blase Anthony Carabello; Kumudha Ramasubbu; Biykem Bozkurt
Journal:  Am J Cardiol       Date:  2008-09-12       Impact factor: 2.778

10.  Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure.

Authors:  Philippe Meyer; Michel White; Marjan Mujib; Anna Nozza; Thomas E Love; Inmaculada Aban; James B Young; William H Wehrmacher; Ali Ahmed
Journal:  Am J Cardiol       Date:  2008-10-17       Impact factor: 2.778

View more
  5 in total

1.  [Digitalis and theophylline: old and superfluous?].

Authors:  M Gosch; P Dovjak
Journal:  Z Gerontol Geriatr       Date:  2013-07       Impact factor: 1.281

Review 2.  Effects of Digoxin in Heart Failure (HF) With Reduced Ejection Fraction (EF).

Authors:  Riya R Parikh; Khushbu R Patel; Joseph V Pergolizzi; Frank Breve; Peter Magnusson
Journal:  Cureus       Date:  2022-03-02

Review 3.  Digitalis for treatment of heart failure in patients in sinus rhythm.

Authors:  William B Hood; Antonio L Dans; Gordon H Guyatt; Roman Jaeschke; John J V McMurray
Journal:  Cochrane Database Syst Rev       Date:  2014-04-28

Review 4.  Contemporary Controversies in Digoxin Use in Systolic Heart Failure.

Authors:  Chonyang L Albert; Forum Kamdar; Mazen Hanna
Journal:  Curr Heart Fail Rep       Date:  2016-10

5.  Machine learning for subtype definition and risk prediction in heart failure, acute coronary syndromes and atrial fibrillation: systematic review of validity and clinical utility.

Authors:  Amitava Banerjee; Suliang Chen; Ghazaleh Fatemifar; Mohamad Zeina; R Thomas Lumbers; Johanna Mielke; Simrat Gill; Dipak Kotecha; Daniel F Freitag; Spiros Denaxas; Harry Hemingway
Journal:  BMC Med       Date:  2021-04-06       Impact factor: 11.150

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.